 Daré Bioscience, Inc. DARE, a leader in womens health innovation, today announced it entered into a 15 million common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC LPC, a Chicago-based institutional investor. Under the terms and conditions of the purchase agreement, Daré will have the right, from time to time and at its sole discretion, to sell up to 15 million of its stock to LPC over a 36-month period, subject to a registration statement covering the resale by LPC of shares issued and sold under the purchase agreement being filed and declared effective by the Securities and Exchange Commission SEC and satisfaction of the other conditions in the purchase agreement. 